(Q34781970)

English

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

David S. Alberts

15

object named as

David S Alberts

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

author name string

Setsuko K Chambers

1

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Mary C Clouser

2

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Amanda F Baker

3

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Denise J Roe

4

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Haiyan Cui

5

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Molly A Brewer

6

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Kenneth D Hatch

7

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Michael S Gordon

8

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Mike F Janicek

9

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Jeffrey D Isaacs

10

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Alan N Gordon

11

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Raymond B Nagle

12

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Heather M Wright

13

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Janice L Cohen

14

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

5320-5328

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Biomarkers of response and resistance to antiangiogenic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Functional significance of VEGFR-2 on ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Diagnosis and management of epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Cancer of the ovary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

7 July 2018

Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3074583

26 October 2018

Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21041183

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-10-0974

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34781970&oldid=2076555196"